Price Chart

Profile

Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.
URL https://www.allogene.com
Investor Relations URL https://ir.allogene.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Feb. 28, 2024 (est.)
Last Earnings Release Nov. 02, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.
URL https://www.allogene.com
Investor Relations URL https://ir.allogene.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Feb. 28, 2024 (est.)
Last Earnings Release Nov. 02, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A